Souvenaid; Fortasyn Connect
Jump to navigation
Jump to search
Introduction
Apparently proprietary blend of omega-3 fatty acids, phospholipids, choline, selenium, uridine, folic acid, vitamin B12, vitamin B6, vitamin C, vitamin E
Indications
- improves some cognitive outcomes in patients with mild Alzheimer's disease (AD)
Dosage
- once-a-day drink taken with breakfast
Adverse effects
- well tolerated, apparently safe[2]
Mechanism of action
- hypothesis/marketing pitch is that Souvenaid improves brain synapse formation & function[4]
- allegedly preserves organisation of brain networks in patients with mild AD*[3]
- allegedly slows hippocampal atrophy
* demonstrated with 'advanced EEG analysis, using the mathematical framework of graph theory'
Clinical trials
More general terms
Components
- fatty acid, omega-3 (Epanova)
- phospholipid
- choline
- selenium [Se]
- uridine
- folic acid; folate; vitamin B9
- vitamin B12; cobalamin
- pyridoxine (a vitamin B6)
- ascorbate; ascorbic acid; vitamin C
- vitamin E
References
- ↑ Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
- ↑ 2.0 2.1 Olde Rikkert MG, Verhey FR, Blesa R et al Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open- label extension study. J Alzheimers Dis. 2015;44(2):471-80. doi:http://dx.doi.org/ 10.3233/JAD-141305. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25322923
- ↑ 3.0 3.1 de Waal H, Stam CJ, Lansbergen MM, Wieggers RL et al The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One. 2014 Jan 27;9(1):e86558. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24475144 Free PMC Article
- ↑ 4.0 4.1 Scheltens P, Twisk JW, Blesa R et al Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012;31(1):225-36. doi:http://dx.doi.org/ 10.3233/JAD-2012-121189. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22766770
- ↑ 5.0 5.1 George J, Nutrient Drink Fails to Aid Cognition in Early Alzheimer's. Researchers suggest study may have been underpowered. MedPage Today. No 03, 2017
Soininen H, Solomon A, Visser PJ et al 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology. Oct 30, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29097166 Free full text <Internet> http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30332-0/fulltext